| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2023 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NGM Biopharmaceuticals Inc | 8 | Q3 2022 | 45.2% |
| Revolution Medicines Inc | 8 | Q3 2022 | 38.8% |
| Nurix Therapeutics Inc | 8 | Q3 2022 | 24.9% |
| RAPT Therapeutics Inc | 8 | Q3 2022 | 9.7% |
| Constellation Pharmaceuticals Inc. | 3 | Q2 2021 | 43.1% |
View Ponoi II Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-08 |
| 4 | 2023-11-17 |
| 4 | 2023-02-01 |
| 4 | 2023-01-25 |
| 4 | 2023-01-23 |
| 4 | 2023-01-17 |
| 4 | 2023-01-12 |
| 4 | 2022-12-14 |
| 4 | 2022-11-23 |
| 13F-HR | 2022-11-14 |
View Ponoi II Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.